| Variables | Early Gp IIb–IIIa inhibitors | Late Gp IIb–IIIa inhibitors |
| (n = 840) | (n = 822) | |
| Age, years | ||
| Median | 61 | 61 |
| Range | 52–70 | 52–70 |
| Sex, n (%) | 642/840 (76.4%) | 641/822 (78.0%) |
| Hypertension, n (%) | 353/838 (42.1%) | 347/822 (42.2%) |
| Diabetes, n (%) | 123/840 (14.6%) | 135/822 (16.4%) |
| Previous MI, n (%) | 67/838 (8.0%) | 80/822 (9.7%) |
| Previous revascularisation, n (%) | 61/792 (7.7%) | 59/770 (7.7%) |
| Smoking, n (%) | 440/840 (52.4%) | 419/822 (51.0%) |
| Hypercholesterolemia, n (%) | 298/840 (35.5%) | 309/820 (37.7%) |
| Killip class III/IV, n (%) | 33/722 (4.6%) | 33/705 (4.7%) |
| Anterior MI, n (%) | 361/831 (43.4%) | 369/819 (45.1%) |
| Symptom onset to Gp IIb–IIIa inhibitor time, minutes* | ||
| Median | 100 | 197 |
| 25–75th percentiles | 65–178 | 144–275 |
| Ischaemia time, minutes | ||
| Median | 193 | 203 |
| 25–75th percentiles | 146–270 | 150–285 |
| Infarct-related artery | ||
| LAD, n (%) | 351(41.7%) | 361 (43.9%) |
| CX, n (%) | 124 (14.7%) | 100 (12.1%) |
| RCA, n (%) | 339 (40.3%) | 336 (40.9%) |
| GRAFT, n (%) | 6 (0.7%) | 6 (0.7%) |
| LM, n (%) | 4 (0.5%) | 5 (0.6%) |
| Multivessel disease, n (%) | 437/757 (57.7%) | 433/737 (58.8%) |
| Follow-up | ||
| Median | 330 | 347 |
| 25–75th percentiles | 30–360 | 30–360 |
All p values are not significant except for the time from symptom onset to administration of Gp IIb–IIIa inhibitors* (p<0.001).
CX, circumflex artery; Gp, glycoprotein; LAD, left descending coronary artery; LM, left main artery; MI, myocardial infarction; RCA, right coronary artery.